Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) has taken a significant step toward expanding its oncology pipeline by entering into a non-binding letter of intent (LOI) with Ifowonco Informatics Incorporated. The LOI is the initial phase in negotiating a definitive agreement that would grant Onco an exclusive option on Ifowonco’s proprietary small-molecule inhibitor program targeting lymphocyte-activation gene 3 (LAG-3), a key immune checkpoint. This move signals a strategic shift in cancer treatment, as LAG-3 inhibitors have traditionally been delivered intravenously as monoclonal antibodies, but Ifowonco’s program focuses on orally available small molecules, which could offer greater convenience and potentially improved patient compliance.
The proposed collaboration aims to combine Ifowonco’s oral immune checkpoint technology with Onco-Innovations’ expertise in DNA damage response (DDR) therapeutics, translational oncology, and clinical development. The companies believe that combining DDR inhibition with LAG-3 blockade could potentially enhance anti-tumour immune responses across multiple solid tumour indications. This is particularly relevant because DDR inhibitors, such as PARP inhibitors, have shown promise in cancers with DNA repair deficiencies, and adding an immune checkpoint inhibitor could amplify the immune system’s ability to attack tumours. The synergy between these two approaches could lead to more effective treatments for patients with solid tumours, a major unmet medical need.
“This potential agreement could position Onco-Innovations at the intersection of precision oncology and next-generation cancer immunotherapy,” said Thomas O’Shaughnessy, CEO of Onco-Innovations, in the press release. The company intends to evaluate the LAG-3 program independently and, where supported by preclinical findings, explore its use alongside DDR-based therapeutic approaches, including Onco’s ONC010 program. This dual-track strategy could accelerate the development of combination therapies that target multiple pathways involved in cancer growth and immune evasion.
The importance of this announcement lies in the potential to bring a new class of LAG-3 inhibitors to the clinic. Currently, LAG-3 inhibitors on the market are monoclonal antibodies that require intravenous infusion, which can be burdensome for patients. An oral small-molecule inhibitor could be administered at home, improving quality of life and reducing healthcare costs. Moreover, the combination with DDR inhibitors could expand the use of immunotherapies to patients who do not respond to existing checkpoint inhibitors, addressing a significant challenge in oncology.
For the industry, this collaboration highlights the growing interest in developing oral versions of immunotherapies and combining them with targeted therapies to overcome resistance. It also underscores the potential of small-molecule approaches to complement or replace biologics in certain settings. The success of this program could pave the way for more accessible and effective cancer treatments, benefiting patients worldwide.
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, with an exclusive worldwide license to patented technology targeting solid tumours. The company’s focus on DDR therapeutics and its commitment to innovative solutions align with this new venture. While the LOI is non-binding, it represents a proactive step toward securing a promising asset that could diversify its pipeline and strengthen its position in the competitive oncology market.
As the company moves forward with negotiations and preclinical evaluations, the potential impact on patient care and the broader biotech sector will be closely watched. The full press release is available at https://ibn.fm/E63Ne. For more information about Onco-Innovations, visit its newsroom at https://ibn.fm/ONNVF.
